TNF Pharmaceuticals (TNFA) Competitors $0.10 -0.01 (-7.42%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.10 +0.00 (+3.96%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsTrendsBuy This Stock TNFA vs. CLRB, BMRA, TAOX, TLPH, CYCN, DWTX, KZIA, TRAW, GNPX, and SNSEShould you be buying TNF Pharmaceuticals stock or one of its competitors? The main competitors of TNF Pharmaceuticals include Cellectar Biosciences (CLRB), Biomerica (BMRA), Synaptogenix (TAOX), Talphera (TLPH), Cyclerion Therapeutics (CYCN), Dogwood Therapeutics (DWTX), Novogen (KZIA), Traws Pharma (TRAW), Genprex (GNPX), and Sensei Biotherapeutics (SNSE). These companies are all part of the "pharmaceutical products" industry. TNF Pharmaceuticals vs. Its Competitors Cellectar Biosciences Biomerica Synaptogenix Talphera Cyclerion Therapeutics Dogwood Therapeutics Novogen Traws Pharma Genprex Sensei Biotherapeutics Cellectar Biosciences (NASDAQ:CLRB) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, media sentiment, profitability and risk. Do institutionals & insiders believe in CLRB or TNFA? 16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are held by institutional investors. 5.0% of Cellectar Biosciences shares are held by insiders. Comparatively, 0.5% of TNF Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility and risk, CLRB or TNFA? Cellectar Biosciences has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, TNF Pharmaceuticals has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500. Does the media prefer CLRB or TNFA? In the previous week, Cellectar Biosciences' average media sentiment score of 0.00 equaled TNF Pharmaceuticals'average media sentiment score. Company Overall Sentiment Cellectar Biosciences Neutral TNF Pharmaceuticals Neutral Is CLRB or TNFA more profitable? TNF Pharmaceuticals' return on equity of -97.38% beat Cellectar Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cellectar BiosciencesN/A -619.70% -158.04% TNF Pharmaceuticals N/A -97.38%-37.37% Do analysts recommend CLRB or TNFA? Cellectar Biosciences presently has a consensus target price of $375.00, indicating a potential upside of 7,844.92%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Cellectar Biosciences is more favorable than TNF Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectar Biosciences 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33TNF Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable earnings and valuation, CLRB or TNFA? Cellectar Biosciences is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCellectar BiosciencesN/AN/A-$44.58M-$21.92-0.22TNF PharmaceuticalsN/AN/A-$23.36M-$6.67-0.02 SummaryTNF Pharmaceuticals beats Cellectar Biosciences on 6 of the 11 factors compared between the two stocks. Get TNF Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TNFA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TNFA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNFA vs. The Competition Export to ExcelMetricTNF PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.43M$2.46B$5.49B$9.54BDividend YieldN/A1.81%4.73%4.09%P/E Ratio-0.028.9728.8323.83Price / SalesN/A437.65372.0766.02Price / CashN/A157.7635.4557.96Price / Book0.044.838.275.54Net Income-$23.36M$31.62M$3.25B$259.28M7 Day Performance-13.53%-5.28%-3.73%-4.68%1 Month Performance-12.78%4.38%4.29%4.36%1 Year PerformanceN/A-2.49%25.87%17.88% TNF Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNFATNF PharmaceuticalsN/A$0.10-7.4%N/AN/A$1.43MN/A-0.026Gap DownCLRBCellectar Biosciences2.6421 of 5 stars$5.13+2.0%$375.00+7,209.9%-92.4%$9.29MN/A-0.2310Positive NewsGap UpBMRABiomerica0.2073 of 5 stars$3.63-7.1%N/A+31.3%$9.27M$5.41M-1.5760Gap DownTAOXSynaptogenixN/A$6.62+1.5%N/AN/A$9.20MN/A-0.664TLPHTalphera2.0565 of 5 stars$0.45+3.5%$5.00+1,018.6%-56.9%$9.16M$650K-0.9919Positive NewsShort Interest ↑Gap UpCYCNCyclerion TherapeuticsN/A$2.83-1.0%N/A-26.5%$9.08M$2.08M-2.4430Positive NewsUpcoming EarningsDWTXDogwood Therapeutics1.44 of 5 stars$4.71-1.2%$10.00+112.3%N/A$9.00MN/A-0.265Positive NewsUpcoming EarningsGap UpKZIANovogen2.7573 of 5 stars$8.90-9.4%$14.00+57.3%-53.2%$8.99M$1.51M0.0012News CoveragePositive NewsShort Interest ↑Gap DownTRAWTraws PharmaN/A$1.62-0.3%N/AN/A$8.98M$230K-0.0517Positive NewsGNPXGenprex1.4699 of 5 stars$0.27+1.8%N/A-86.3%$8.85MN/A0.0020Positive NewsUpcoming EarningsGap DownSNSESensei Biotherapeutics4.5235 of 5 stars$7.02+0.5%$90.00+1,183.0%-21.2%$8.84MN/A-0.3140Positive NewsUpcoming EarningsGap Down Related Companies and Tools Related Companies Cellectar Biosciences Alternatives Biomerica Alternatives Synaptogenix Alternatives Talphera Alternatives Cyclerion Therapeutics Alternatives Dogwood Therapeutics Alternatives Novogen Alternatives Traws Pharma Alternatives Genprex Alternatives Sensei Biotherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNFA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TNF Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TNF Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
